These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Shares of Precigen (PGEN) and Mineralys Therapeutics (MLYS) recently surged over 140% due to distinct catalysts. Precigen's 155% gain followed FDA approval of its first drug, Papzimeos, for recurrent respiratory papillomatosis, a rare disease, with analysts projecting significant revenue potential from its high list price. Mineralys' 146% rise was driven by a successful $287.5 million secondary offering and promising Phase 3 data for its hypertension candidate, lorundrostat, which demonstrated superior efficacy compared to a similar AstraZeneca drug. However, despite strong trial results, concerns persist regarding Mineralys' approval timeline and potential market competition, prompting a cautious outlook for its high market capitalization.

Analysis

Two biotechnology firms, Precigen (PGEN) and Mineralys Therapeutics (MLYS), experienced significant stock appreciation, with gains of 155% and 146% respectively, driven by fundamentally different catalysts. Precigen's surge is directly tied to a major de-risking event: the full FDA approval of its first drug, Papzimeos, an immunotherapy for a rare disease with an addressable population of 27,000. As the sole approved treatment, and with trial data showing a durable response in a majority of patients at 24 months, Papzimeos has a peak sales potential exceeding $1 billion annually, which contrasts sharply with the company's current $1.3 billion market capitalization. In contrast, Mineralys' rally was fueled by a successful $287.5 million secondary offering and Phase 3 data for its hypertension candidate, lorundrostat, which showed a superior systolic pressure reduction at six weeks compared to AstraZeneca's competing drug. However, this is undermined by significant execution risk. The capital raise, despite a cash runway projected into 2027, signals potential delays in its regulatory submission, creating a critical timing risk that could allow AstraZeneca's candidate to establish a first-mover advantage in the market. This concern weighs heavily on Mineralys' substantial $2.7 billion valuation.

Key Decisions for Investors

• Precigen's recent FDA approval for Papzimeos has significantly de-risked its profile, and investors may see its $1.3 billion market cap as undervalued relative to the drug's billion-dollar peak sales potential in an uncontested market.
• Investors should approach Mineralys Therapeutics with caution; despite promising clinical data, its $2.7 billion valuation appears stretched given the significant competitive timing risk from AstraZeneca and the potential for shareholder dilution implied by its recent capital raise.
• The primary factor to monitor for Mineralys is its regulatory submission timeline for lorundrostat, as any acceleration could mitigate the competitive threat, while further delays would amplify the existing risks.